Reimbursed Care Access in Austria

Currently classified under Austria's narcotics control regime (Suchtmittelgesetz) with no authorised routine medical use or broad reimbursement; medical access is limited to approved clinical research. Specific psilocybin clinical trials have been authorised for treatment‑resistant depression at Austrian institutions (e.g., an authorised CTIS trial with decision date 30 January 2025), which provides a legal route for patient access only within that trial protocol and under the trial sponsor's terms #. Outside of authorised research there is no routine prescribing, and possession/supply remain prosecutable under the SMG. For legal context on controlled substances and prosecutable acts (including psilocybin‑containing fungi), see Austria’s Suchtmittelgesetz. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Relevant possession, supply or distribution is governed by the Suchtmittelgesetz and penal provisions therein. #.

Esketamine (commercially Spravato) is authorised at the EU level for treatment‑resistant major depressive disorder and is available in EU member states (including Austria) under the product’s marketing authorisation; the EMA product information describes supervised clinic administration and safety restrictions. #.

In Austria esketamine has been implemented into clinical practice since the EU authorisation period and reporting indicates ambulatory use for depression has been adopted in psychiatric practice; Austrian press and clinical commentary note that its use is typically restricted to psychiatrists in certified settings and administered under supervision because of acute safety risks (dissociation, blood‑pressure effects) and the need for monitoring. #.

Reimbursement: esketamine’s availability does not automatically guarantee broad, routine coverage by Austria’s statutory health insurance (Gebietskrankenkassen); reimbursement decisions are typically subject to national/regional pharmacy‑reimbursement and hospital/clinic contracting processes and may be handled on a case‑by‑case basis (special prescription pathways, hospital billing or private pay). In practice many patients receive esketamine in specialist outpatient psychiatric clinics and payment/coverage varies by provider arrangements and individual entitlement. For the EU authorisation rationale and clinical administration requirements see the EMA product information. #.

Ketamine (racemate) and S‑ketamine are authorised medicinal products for anaesthesia and analgesia in Austria and can be legally prescribed/used by physicians; beyond anaesthesia, ketamine is used off‑label in psychiatry (intravenous infusions or other formulations) for treatment‑resistant depression and certain pain indications under specialist supervision. Clinical and academic Austrian sources describe the growing use of ketamine infusions for refractory depression and chronic pain in specialist centres, with administration typically by hospital or specialised outpatient clinics and oversight by psychiatrists, anesthesiologists or pain specialists. #.

Reimbursement and access nuance: because IV or off‑label ketamine protocols for depression are not an EMA‑labelled psychiatric indication (except esketamine/Spravato) their routine reimbursement by Austria’s statutory health insurers is limited — many such treatments are delivered in private specialist settings or billed under hospital care codes; individual reimbursement may be possible in specific circumstances (e.g., inpatient hospital treatment, documented therapeutic necessity) but is not generally standardised. Prescribing physicians rely on medical judgement ('Therapiefreiheit') while complying with narcotics recordkeeping and pharmacy regulations; ketamine as an anaesthetic remains a standard reimbursed hospital drug when used for approved indications. For legal scheduling and prescribing controls see Austria’s Suchtmittelgesetz and psychotropen/narcotics regulations. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Possession, manufacture, or distribution outside authorised research is prosecutable under the SMG. There are occasional international research efforts but Austria currently offers no routine medical access pathway for DMT outside formal trials. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Supply, possession or use outside authorised trials may be subject to criminal sanction under Austrian law (SMG). #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no routine medical or reimbursed treatment pathway for ibogaine in Austria; any therapeutic use would need to be within authorised research. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Preparations containing DMT (as in ayahuasca) fall under the same prohibitions and their supply/use is prosecutable except inside authorised research protocols. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Possession or trafficking of mescaline (and mescaline‑containing cacti insofar as they are regulated) is subject to SMG provisions. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. New psychoactive phenethylamines (2C family and analogues) are covered by Austria’s narcotics and psychotropic substance regulations and are not available for routine medical prescribing. #.